ID   JSC-1
AC   CVCL_3728
AS   CVCL_B054
SY   JSC1; JSC
DR   CLO; CLO_0007039
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2769
DR   ATCC; JHU-32
DR   BioSample; SAMN03471783
DR   cancercelllines; CVCL_3728
DR   Cell_Model_Passport; SIDM00688
DR   Cosmic; 1588564
DR   Cosmic-CLP; 1327769
DR   DepMap; ACH-002253
DR   EGA; EGAS00001000978
DR   GDSC; 1327769
DR   GEO; GSM634739
DR   GEO; GSM710424
DR   GEO; GSM710440
DR   GEO; GSM827379
DR   GEO; GSM1669964
DR   GEO; GSM3150247
DR   IARC_TP53; 23657
DR   LINCS_LDP; LCL-1959
DR   PharmacoDB; JSC1_711_2019
DR   PRIDE; PXD012087
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3728
DR   Wikidata; Q54899065
RX   PubMed=11024147;
RX   PubMed=15613351;
RX   PubMed=17121789;
RX   PubMed=20215515;
RX   PubMed=21685375;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
RX   PubMed=36094314;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 48 hours (PubMed=11024147).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
CC   Omics: Array-based CGH.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.79%; Native American=0.09%; East Asian, North=0.94%; East Asian, South=0%; South Asian=1.9%; European, North=65.05%; European, South=31.24% (PubMed=30894373).
CC   Misspelling: JCS-1; Note=Occasionally.
CC   Discontinued: ATCC; CRL-2769; true.
CC   Discontinued: ATCC; JHU-32; true.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ATCC; Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9,14
ST   D16S539: 11,12
ST   D5S818: 12
ST   D7S820: 9
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 14,18
DI   NCIt; C6915; Primary effusion lymphoma
DI   ORDO; Orphanet_48686; Primary effusion lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 36
//
RX   PubMed=11024147; DOI=10.1128/JVI.74.21.10187-10193.2000;
RA   Cannon J.S., Ciufo D., Hawkins A.L., Griffin C.A., Borowitz M.J.,
RA   Hayward G.S., Ambinder R.F.;
RT   "A new primary effusion lymphoma-derived cell line yields a highly
RT   infectious Kaposi's sarcoma herpesvirus-containing supernatant.";
RL   J. Virol. 74:10187-10193(2000).
//
RX   PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005;
RA   Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E.,
RA   Knowles D.M.;
RT   "Distinct subsets of primary effusion lymphoma can be identified based
RT   on their cellular gene expression profile and viral association.";
RL   J. Virol. 79:1244-1251(2005).
//
RX   PubMed=17121789; DOI=10.1128/JVI.01757-06;
RA   Burd C.E., Sin S.-H., Dittmer D.P.;
RT   "Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus
RT   lymphomas: implications for therapy.";
RL   J. Virol. 81:1912-1922(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21685375; DOI=10.1182/blood-2010-12-323659;
RA   Roy D., Sin S.-H., Damania B., Dittmer D.P.;
RT   "Tumor suppressor genes FHIT and WWOX are deleted in primary effusion
RT   lymphoma (PEL) cell lines.";
RL   Blood 118:E32-E39(2011).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//
RX   PubMed=36094314; DOI=10.1128/JVI.00739-22;
RA   Ding W.-Y., Wang C., Narita Y., Wang H.-B., Leong M.M.L., Huang A.,
RA   Liao Y.-F., Liu X.-F., Okuno Y., Kimura H., Gewurz B.E., Teng M.-X.,
RA   Jin S.-L., Sato Y., Zhao B.;
RT   "The Epstein-Barr virus enhancer interaction landscapes in
RT   virus-associated cancer cell lines.";
RL   J. Virol. 96:e0073922.1-e0073922.11(2022).
//